Presentation
Lacidip 2: Each film coated tablet contains Lacidipine BP 2 mg.
Lacidip 4: Each film coated tablet contains Lacidipine BP 4 mg.
Descriptions
Lacidipine is a potent dihydropyridine calcium antagonist mainly selective for calcium channels in the vascular smooth muscle. It dilates peripheral arterioles resulting in reduced peripheral vascular resistance and blood pressure.
Indications
Lacidipine is indicated for hypertension.
Dosage & Administration
Initially 2 mg as a single daily dose, preferably in the morning; increased after 3-4 weeks to 4 mg daily, then if necessary to 6 mg daily.
Side Effects
Flushing, palpitation, oedema; headache, dizziness; rarely gastro-intestinal disturbances, gum hyperplasia, aggravation of angina, mood disturbances, asthenia, polyuria, muscle cramps, skin rash (including pruritus and erythema).
Precautions
Cardiac conduction abnormalities; poor cardiac reserve; grapefruit juice (may affect metabolism) should be avoided. Special precaution is needed for hepatic impaired patients because antihypertensive effect possibly increased.
Contraindications
Known hypersensitivity to Lacidipine. Cardiogenic shock, unstable angina, aortic stenosis; avoid within 1 month of myocardial infarction; acute porphyria.
Use in Pregnancy & Lactation
Pregnancy category C. Lacidipine should not be taken if pregnant, likely to get pregnant or are breast-feeding. Because lacidipine is excreted through the breast milk and there is no established data on the safety of lacidipine during pregnancy.
Drug Interaction
Additive hypotensive effect with other antihypertensives (e.g. diuretics, b-blockers, ACE inhibitors). Increased plasma concentration with cimetidine. Elimination and metabolism may be altered by potent CYP3A4 inhibitors and inducers. Increased risk of ventricular arrhythmias with drugs that prolong QT interval (e.g. class I and III antiarrhythmics, TCAs, certain antipsychotics, antibiotics and antihistamines).
Overdose
There have been no recorded cases of lacidipine overdosage. As with other dihydropyridines, overdosage might be expected to cause excessive peripheral vasodilatation with marked hypotension and reflex tachycardia.
Commercial Packaging
Lacidip 2: Each box contains 5 blister strips of 10 tablets.
Lacidip 4: Each box contains 3 blister strips of 10 tablets.
Lacidip 2: Each film coated tablet contains Lacidipine BP 2 mg.
Lacidip 4: Each film coated tablet contains Lacidipine BP 4 mg.
Descriptions
Lacidipine is a potent dihydropyridine calcium antagonist mainly selective for calcium channels in the vascular smooth muscle. It dilates peripheral arterioles resulting in reduced peripheral vascular resistance and blood pressure.
Indications
Lacidipine is indicated for hypertension.
Dosage & Administration
Initially 2 mg as a single daily dose, preferably in the morning; increased after 3-4 weeks to 4 mg daily, then if necessary to 6 mg daily.
Side Effects
Flushing, palpitation, oedema; headache, dizziness; rarely gastro-intestinal disturbances, gum hyperplasia, aggravation of angina, mood disturbances, asthenia, polyuria, muscle cramps, skin rash (including pruritus and erythema).
Precautions
Cardiac conduction abnormalities; poor cardiac reserve; grapefruit juice (may affect metabolism) should be avoided. Special precaution is needed for hepatic impaired patients because antihypertensive effect possibly increased.
Contraindications
Known hypersensitivity to Lacidipine. Cardiogenic shock, unstable angina, aortic stenosis; avoid within 1 month of myocardial infarction; acute porphyria.
Use in Pregnancy & Lactation
Pregnancy category C. Lacidipine should not be taken if pregnant, likely to get pregnant or are breast-feeding. Because lacidipine is excreted through the breast milk and there is no established data on the safety of lacidipine during pregnancy.
Drug Interaction
Additive hypotensive effect with other antihypertensives (e.g. diuretics, b-blockers, ACE inhibitors). Increased plasma concentration with cimetidine. Elimination and metabolism may be altered by potent CYP3A4 inhibitors and inducers. Increased risk of ventricular arrhythmias with drugs that prolong QT interval (e.g. class I and III antiarrhythmics, TCAs, certain antipsychotics, antibiotics and antihistamines).
Overdose
There have been no recorded cases of lacidipine overdosage. As with other dihydropyridines, overdosage might be expected to cause excessive peripheral vasodilatation with marked hypotension and reflex tachycardia.
Commercial Packaging
Lacidip 2: Each box contains 5 blister strips of 10 tablets.
Lacidip 4: Each box contains 3 blister strips of 10 tablets.
0 comments:
Post a Comment